Skip to content
TrialScanner

NCT03579966

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Phase 3TerminatedCPRXLead

Registry record

Lead sponsor
Catalyst Pharmaceuticals, Inc.
Conditions
Myasthenia Gravis, MuSK; AChR Myasthenia Gravis
Primary completion
Aug 5, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03579966 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03579966: Long Term Safety Study of... | TrialScanner